Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
116.03
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
89
90
Next >
Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short
July 30, 2024
Merck reported better-than-expected earnings on Tuesday. But the pharmaceutical giant's soft outlook could pressure Merck stock.
Via
Investor's Business Daily
Merck Announces Second-Quarter 2024 Financial Results
July 30, 2024
From
Merck & Co., Inc.
Via
Business Wire
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Merck & Co's Options: A Look at What the Big Money is Thinking
July 26, 2024
Via
Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
July 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Smart Money Is Betting Big In MRK Options
July 25, 2024
Via
Benzinga
Merck & Co Inc. DCF Valuation: Is The Stock Undervalued?
July 19, 2024
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections.
Via
Talk Markets
Merck & Co's Options Frenzy: What You Need to Know
July 18, 2024
Via
Benzinga
Earnings Divide Dow Industrials As Crux Of Q2 Season Approaches
July 25, 2024
The Dow index declined 1.3% on Wednesday, undercutting short-term support.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
July 23, 2024
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints.
Via
Benzinga
Merck Announces Fourth-Quarter 2024 Dividend
July 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
July 23, 2024
Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Evaluating Merck & Co Against Peers In Pharmaceuticals Industry
July 17, 2024
Via
Benzinga
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
July 17, 2024
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals.
Via
Chartmill
Merck's Acquisition of EyeBio Finalized
July 12, 2024
Merk announced the acquisition of EyeBio, introducing a novel candidate to the company's pipeline, Restoret.
Via
Benzinga
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
July 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Via
The Motley Fool
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
July 21, 2024
This fund has a basket of growth, income, and value stocks.
Via
The Motley Fool
Topics
ETFs
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
The Nasdaq tumbled amid chip woes.
Via
Investor's Business Daily
Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
July 18, 2024
Merck secures legal victory as 3rd U.S. Circuit Court of Appeals upholds dismissal of 1,200 lawsuits over Zostavax shingles vaccine.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
2 Magnificent Stocks to Buy With $500
July 18, 2024
These reliable healthcare companies look attractive no matter how you slice it.
Via
The Motley Fool
3 Top Cancer Treatment Stocks to Buy Now
July 17, 2024
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term.
Via
InvestorPlace
3 Biotech Stocks to Buy in Case of Another Pandemic
July 16, 2024
These are three of the best biotech stocks to keep an eye on as the industry helps governments prepare for the next pandemic.
Via
InvestorPlace
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
July 16, 2024
From
Merck & Co., Inc.
Via
Business Wire
Forget Nvidia: Billionaires Are Dumping It and Piling Into These 3 Surprising Value Stocks Instead
July 16, 2024
Nvidia's three most-prominent billionaire sellers opted to put their respective fund's capital to work in a trio of brand-name companies trading at a discount.
Via
The Motley Fool
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
July 12, 2024
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer...
Via
Benzinga
Merck Completes Acquisition of EyeBio
July 12, 2024
From
Merck & Co., Inc.
Via
Business Wire
3 Under-$10 Biotech Stocks That Could Make You Rich
July 11, 2024
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
89
90
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.